Identifying and validating novel targets with in vivo disease models: Guidelines for study design

Drug Discovery Today

Volumn 12, Issue 11-12, 2007, Pages 446-451

  Anders, Hans Joachim ^a   Vielhauer, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL WELFARE; DISEASE MODEL; IN VIVO STUDY; METHODOLOGY; MUTANT; PRACTICE GUIDELINE; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY; HUMANS; MICE; MICE, KNOCKOUT; PHARMACOLOGY; PHARMACOLOGY, CLINICAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 34249080326     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.04.001     Document Type: Review

References (37)

1. Persidis A. Data mining in biotechnology. Nat. Biotechnol. 18 (2000) 237-238
2. Butcher E.C., et al. Systems biology in drug discovery. Nat. Biotechnol. 22 (2004) 1253-1259
3. Hong J.W., et al. Integrated nanoliter systems. Nat. Biotechnol. 21 (2003) 1179-1183
4. Xia X.G., et al. Transgenic RNAi: accelerating and expanding reverse genetics in mammals. Transgenic Res. 15 (2006) 271-275
5. Glaser S., et al. Current issues in mouse genome engineering. Nat. Genet. 37 (2005) 1187-1193
6. Chatterjee-Kishore M., et al. Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation. Drug Discov. Today 10 (2005) 1559-1565
7. Fewell G.D., et al. Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discov. Today 11 (2006) 975-982
8. Zhang D., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (2004) 1522-1526
9. Lindsay M.A. Target discovery. Nat. Rev. Drug Discov. 2 (2003) 831-838
10. Anders H.J., et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 109 (2002) 251-259
11. Horuk R., et al. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29 (2003) 369-375
12. Kerjaschki D., et al. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J. Am. Soc. Nephrol. 7 (1996) 2518-2526
13. Jefferson J.A., et al. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J. Nephrol. 12 (1999) 297-307
14. Cosgrove D., et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev. 10 (1996) 2981-2992
15. Sugimoto H., et al. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7321-7326
16. Christensen S.R., et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202 (2005) 321-331
17. Wu X., et al. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54 (2006) 336-342
18. Wang Y., et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 58 (2000) 1797-1804
19. Xie C., et al. Strain distribution pattern of susceptibility to immune-mediated nephritis. J. Immunol. 172 (2004) 5047-5055
20. Holdsworth S.R., et al. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 55 (1999) 1198-1216
21. Mohan C., et al. Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J. Immunol. 159 (1997) 454-465
22. Mohan C., et al. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J. Clin. Invest. 101 (1998) 1362-1372
23. Mohan C., et al. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J. Immunol. 162 (1999) 6492-6502
24. Vidal S., et al. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J. Clin. Invest. 101 (1998) 696-702
25. Leiter E.H., et al. Susceptibility to db gene and streptozotocin-induced diabetes in C57BL mice: control by gender-associated, MHC-unlinked traits. Immunogenetics 26 (1987) 6-13
26. Martins P.N. Learning curve, surgical results and operative complications for kidney transplantation in mice. Microsurgery 26 (2006) 590-593
27. Benigni A., et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14 (2003) 1816-1824
28. Flecknell P. Replacement, reduction and refinement. ALTEX 19 (2002) 73-78
29. Holden C. A pivotal year for lab animal welfare. Science 232 (1986) 147-150
30. Mead R. The Design of Experiments (1988), Cambridge University Press
31. Cohen J. Statistical Power Analysis for the Behavioral Sciences (1988), Lawrence Erlbaum Associates
32. Dytham C. Choosing and Using Statistics. A Biologist's Guide (2003), Blackwell Publishing
33. Forster R., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99 (1999) 23-33
34. Patole P.S., et al. G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 16 (2005) 3273-3280
35. Lewandoski M. Conditional control of gene expression in the mouse. Nat. Rev. Genet. 2 (2001) 743-755
36. Duffield J.S., et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am. J. Pathol. 167 (2005) 1207-1219
37. Bruhl H., et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. Immunol. 172 (2004) 890-898